If you are looking for an answer to the question What is Artificial Intelligence? and you only have a minute, then here's the definition the Association for the Advancement of Artificial Intelligence offers on its home page: "the scientific understanding of the mechanisms underlying thought and intelligent behavior and their embodiment in machines."
However, if you are fortunate enough to have more than a minute, then please get ready to embark upon an exciting journey exploring AI (but beware, it could last a lifetime) …
Now, a UT Dallas researcher is giving the fantasy of robotic friends a practical edge with a robot that teaches social skills to children with Autism Spectrum Disorder (ASD). "It's not to replace therapy with humans, but you can deliver a social skills lesson in a less threatening way, and the robot can deliver the same lesson multiple times," Rollins said. During a lesson, the robot explains a social situation to the child with ASD. Media Contact: Ben Porter, UT Dallas, (972) 883-2193, [email protected] or the Office of Media Relations, UT Dallas, (972) 883-2155, [email protected].
A team of researchers at the Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School (HMS) in Boston have been working on developing artificial intelligence (AI) tools with potential to significantly change and improve accuracy in cancer and other disease diagnosis. Noting that pathology methods for diagnosing disease have stayed largely the same for the past 100 years with tissue samples manually reviewed under a microscope, the investigative work suggests diagnostic accuracy can be improved by using computers to interpret pathology images. "Our AI method is based on deep learning, a machine-learning algorithm used for a range of applications including speech recognition and image recognition," said Dr. Andrew Beck director of Bioinformatics at the Cancer Research Institute at Beth Israel Deaconess Medical Center (BIDMC) in press release. Beck, who is also an associate professor at Harvard Medical School said the approach teaches machines to interpret the complex patterns and structure observed in real-life data by building multi-layer artificial neural networks thought to be similar to how the learning occurs in the brain neocortex, where thinking occurs. The Beck lab's approach was recently tested in a competition at the annual meeting of the International Symposium of Biomedical Imaging (ISBI) held in Prague, Czech Republic, in April.
Ray Dalio, the founder of Bridgewater Associates, the largest hedge fund in the world, hired IBM's Watson programming team to incorporate artificial intelligence into the investment process. Later this year, I will be doing something similar so stay tuned to learn more about this exciting endeavor. Today, we have Jamie Wise from BUZZ Indexes, based in Toronto, who recently launched an Artificial Intelligence driven ETF based index fund BUZ (US). The investment process uses natural language processing software and artificial intelligence to scour the Internet for tweets, blogs, and searches for company names. One of the most interesting things is that the software is able distinguish between someone typing amazon when talking about a bad product they bought on line and AMZN and a bad outlook for the stock.
At the International Symposium on Biomedical Imaging in Prague, a Harvard-based artificial intelligence system won the Camelyon16 challenge, a competition comprised of participants introducing their individual AI systems and its ability to facilitate automated lymph node metastasis diagnosis. Referred to as PathAl, the computing system identifies cancerous cells through a mechanism referred to as deep learning--an algorithmic technique that accumulates copious amounts of unstructured data and organizes it into clusters, before analyzing it for patterns. Deep learning is predominately utilized in speech recognition systems like Apple's Siri and Microsoft's Cortana. According to one of the challenge's organizers, Jeroen van der Laak of Radboud University Medical Center in Netherlands, the technology featured in the competition went "way beyond" his expectations, as the AI's accuracy proved strikingly close to that of human beings. In addition, van der Laak said AI technology has the propensity to intrinsically redefine the way histopathological images are handled in the medical community.
The Alphabet subsidiary is partnering with a UK hospital to test whether its algorithm can help diagnose diabetic retinopathy and age-related macular degeneration sooner. Diabetic retinopathy and age-related macular degeneration are serious conditions that can lead to loss of eyesight, and they affect more than 100 million people across the globe. The good news is that early detection can minimize the damage, but the bad news is that diagnosis can often take time. Now, Google DeepMind, a subsidiary of Google parent company Alphabet Inc., hopes to speed up the process by applying artificial intelligence. Optical coherence tomography, a noninvasive imaging technique that can produce 3-D scans of the eye, as well as digital scans of the back of the eye can be used to diagnose both diabetic retinopathy and age-related macular degeneration.
Scientists in the Netherlands are looking to pair artificial intelligence (AI), or machine learning, with MRI techniques that measure blood perfusion in the brain. This approach, said the researchers -- diagnoses early forms of dementia and predicts the onset of Alzheimer's disease with between 82 and 90 percent accuracy. Though there is no cure for Alzheimer's, experts believe that early diagnosis could improve patient outcomes and alleviate the healthcare system's financial burden associated with the disease. According to the Alzheimer's Association, only 45 percent of patients and their caregivers dealing with the disease are aware of the diagnosis. Recent Alzheimer's research suggests that it may be possible to isolate biomarkers in the blood to diagnose the disease, demonstrated by scientists at Rowan University.
IBM announced a deal with sports and fitness retailer Under Armour Inc. to use machine learning technology from Watson and showed off an application for diabetic care developed with the supercomputer's data, highlighting the company's effort to expand Watson's capabilities for the health-care industry. IBM and Under Armour released an updated fitness application for Apple Inc.'s iPhones that uses data powered by Watson, IBM Chief Executive Officer Ginni Rometty said Wednesday in a speech at the International Consumer Electronics Show in Las Vegas. Separately, Medtronic Plc CEO Omar Ishrak joined Rometty on stage to unveil a prototype for a diabetes-management app that tests have shown may be capable of predicting hypoglycemic events as early as three hours in advance. The application still needs to go through regulatory review -- it will roll out this summer, Rometty said. The ability to predict the hypoglycemic events is a "breakthrough," she said.
WIRE)--How do our brains learn and understand the world? That question is of paramount importance to both neuroscientists and technologists who want to build intelligent machines. It has been understood for over a hundred years that the inputs and outputs of the brain are constantly changing sequences of patterns and therefore learning and recalling sequences must be a fundamental operation of neurons. Numerous proposals have been made for how neural networks might learn sequences. However, these proposals did not match the anatomy and function observed in the brain.
Emerald Medical Applications Corp. (OTCQB: MRLA), an Israeli-based company engaged in the development and sale of its proprietary DermaCompare cloud-based, artificial intelligence technology for the early diagnosis of Melanoma/skin cancer, today announced entry into a cooperation agreement with Terem, one of Israel's largest community-based, emergency healthcare providers with 17 medical facilities, serving over 700,000 patients throughout Israel. Starting in April 2016, Emerald will begin to offer its DermaCompare technology at each of Terem's clinics throughout Israel, offering advanced dermatological examinations, diagnosisand treatment led by a leading professional Dermatologists. DermaCompare is Emerald's cloud-based, artificial, intelligence technology using Total Body Photography imaging which is capable of being automatically compared to a patient's previous images to diagnose and detect the presence of Melanoma in its earliest stages. Lior Wayn, Emerald's CEO, stated that "DermaCompare, Emerald's FDA approved, HIPPA compliant software technology, which can be downloaded from any Mac or Android based App store, enables physicians andtheir patients, using virtually any digital camera, including cell phones, iPads, tablets and other similar devices, to take Total Body Photography images and, in real-time, transmit these images for dermatological evaluation and identification of suspicious moles, lesions and other skin conditions. These images are then compared using Emerald's cloud database, as well as the patients previous Total Body Photography images, which will dramatically enhance a physician's ability to detect Melanoma earlier, more accurately and more efficient than other means of diagnosis."